(Q40748887)

English

Silver-Enhanced In Situ Hybridization as an Alternative to Fluorescence In Situ Hybridization for Assaying HER2 Amplification in Clinical Breast Cancer

scientific article published on 27 December 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

23 September 2017

Silver-Enhanced In Situ Hybridization as an Alternative to Fluorescence In Situ Hybridization for Assaying HER2 Amplification in Clinical Breast Cancer (English)

1 reference

Europe PubMed Central

23 September 2017

author name string

Kyeongmee Park

1

1 reference

Europe PubMed Central

23 September 2017

Sehwan Han

2

1 reference

Europe PubMed Central

23 September 2017

Jung-Yeon Kim

3

1 reference

Europe PubMed Central

23 September 2017

Hyun-Jung Kim

4

1 reference

Europe PubMed Central

23 September 2017

Ji Eun Kwon

5

1 reference

Europe PubMed Central

23 September 2017

Geumhee Gwak

6

1 reference

Europe PubMed Central

23 September 2017

publication date

27 December 2011

1 reference

Europe PubMed Central

23 September 2017

Journal of breast cancer

1 reference

Europe PubMed Central

23 September 2017

14

1 reference

Europe PubMed Central

23 September 2017

4

1 reference

Europe PubMed Central

23 September 2017

276-282

1 reference

Europe PubMed Central

23 September 2017

copyright license

Creative Commons Attribution-NonCommercial 3.0 Unported

1 January 2011

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Emerging technologies for assessing HER2 amplification

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3268923

24 September 2017

The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3268923

24 September 2017

Metallographic in situ hybridization

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3268923

24 September 2017

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3268923

24 September 2017

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3268923

24 September 2017

Dual-colour chromogenic in situ hybridization for testing of HER-2 oncogene amplification in archival breast tumours

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3268923

24 September 2017

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3268923

24 September 2017

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3268923

24 September 2017

Comparing fluorescence in situ hybridization and chromogenic in situ hybridization methods to determine the HER2/neu status in primary breast carcinoma using tissue microarray.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3268923

24 September 2017

Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3268923

24 September 2017

Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3268923

24 September 2017

Human epidermal growth factor receptor 2 testing in 2010: does chromosome 17 centromere copy number make any difference?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3268923

19 August 2018

Achieving 95% cross-methodological concordance in HER2 testing: causes and implications of discordant cases.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3268923

19 August 2018

Silver in situ hybridization (SISH) for determination of HER2 gene status in breast carcinoma: comparison with FISH and assessment of interobserver reproducibility.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3268923

19 August 2018

HER-2/neu expression in primary and metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3268923

19 August 2018

Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of A

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3268923

19 August 2018

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3268923

19 August 2018

HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3268923

19 August 2018

Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3268923

19 August 2018

c-erbB-2 protein overexpression and p53 immunoreaction in primary and recurrent breast cancer tissues

1 reference

https://pubmed.ncbi.nlm.nih.gov/22323913

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/22323913

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.4048/JBC.2011.14.4.276

1 reference

Europe PubMed Central

23 September 2017

1 reference

Europe PubMed Central

23 September 2017

1 reference

Europe PubMed Central

23 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40748887&oldid=1906671869"